Delving into the Latest Updates on Beijing Wellso Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Cardiovascular Diseases

Small molecule drug

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	5
Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6
Herbal medicine	1

Top 5 Target	Count

Opioid receptors	2
HTR3(5-hydroxytryptamine receptors, ionotropic (HTR3))	1
β1-adrenergic receptor(Beta-1 adrenergic receptor)	1
mAChRs(Muscarinic acetylcholine receptor)	1
Cav2.1(calcium voltage-gated channel subunit alpha1 A)	1

主要研究目的：以北京华素制药股份有限公司持有的盐酸曲唑酮缓释片为受试制剂，以AZ. CHIM.RIUN. ANGELINI FRANCESCO ACRAF S.P.A.持证的盐酸曲唑酮缓释片（商品名：TRITTICO®，规格：150 mg）为参比制剂，通过单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉临床试验来评价两种制剂在餐后条件下的生物等效性。次要研究目的：观察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of trazodone hydrochloride extended-release tablets (licensed by Beijing Huasu Pharmaceutical Co., Ltd.) under postprandial conditions using trazodone hydrochloride extended-release tablets (trade name: TRITTICO®, strength: 150 mg) certified by AZ. CHIM. RIUN. ANGELINI FRANCESCO ACRAF S.P.A. as the test formulation and trazodone hydrochloride extended-release tablets (licensed by AZ. CHIM. RIUN. ANGELINI FRANCESCO ACRAF S.P.A.) as the reference formulation through a single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover clinical trial. Secondary objective: To observe the safety of the test and reference formulations in healthy trial participants.

Start Date07 Apr 2026

Sponsor / Collaborator

Beijing Wellso Pharmaceutical Co., Ltd.

CTR20260235

/ CompletedNot Applicable

多替诺雷片空腹生物等效性试验

[Translation] Bioequivalence test of dotenoroxetine tablets on an empty stomach

主要研究目的：研究空腹状态下单次口服受试制剂多替诺雷片（规格：2 mg，北京华素制药股份有限公司生产）与参比制剂多替诺雷片（URECE®，规格：2mg，株式会社富士薬品生产）在健康成年参与者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂多替诺雷片（规格：2mg）和参比制剂多替诺雷片（URECE®，规格：2mg）在健康成年参与者中的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation domenorrhea tablets (2 mg, manufactured by Beijing Huasu Pharmaceutical Co., Ltd.) and the reference formulation domenorrhea tablets (URECE®, 2 mg, manufactured by Fuji Pharmaceutical Co., Ltd.) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary objective: To evaluate the safety of the test formulation domenorrhea tablets (2 mg) and the reference formulation domenorrhea tablets (URECE®, 2 mg) in healthy adult participants.

Start Date01 Feb 2026

Sponsor / Collaborator

Beijing Wellso Pharmaceutical Co., Ltd.

CTR20260044

/ CompletedNot Applicable

盐酸曲唑酮缓释片在健康试验参与者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹状态下的生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover, fasting bioequivalence study of trazodone hydrochloride extended-release tablets in healthy trial participants.

主要研究目的：以北京华素制药股份有限公司持有的盐酸曲唑酮缓释片为受试制剂，以AZ. CHIM.RIUN. ANGELINI FRANCESCO ACRAF S.P.A.持证的盐酸曲唑酮缓释片（商品名：TRITTICO®，规格：150 mg）为参比制剂，通过单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉临床试验来评价两种制剂在空腹条件下的生物等效性。次要研究目的：观察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of trazodone hydrochloride extended-release tablets (licensed by Beijing Huasu Pharmaceutical Co., Ltd.) under fasting conditions using trazodone hydrochloride extended-release tablets (trade name: TRITTICO®, strength: 150 mg) certified by AZ. CHIM. RIUN. ANGELINI FRANCESCO ACRAF S.P.A. as the test formulation and trazodone hydrochloride extended-release tablets (licensed by AZ. CHIM. RIUN. ANGELINI FRANCESCO ACRAF S.P.A.) as the reference formulation through a single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover clinical trial. Secondary objective: To observe the safety of the test and reference formulations in healthy trial participants.

Start Date26 Jan 2026

Sponsor / Collaborator

Beijing Wellso Pharmaceutical Co., Ltd.

100 Clinical Results associated with Beijing Wellso Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Wellso Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Beijing Wellso Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Wellso Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

6

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

L-Phencynonate Hydrochloride ( mAChRs )	Motion Sickness More	Approved
Bisoprolol Fumarate ( β1-adrenergic receptor )	Essential Hypertension More	Approved
Oxycodone Hydrochloride ( Opioid receptors )	Pain More	Approved
Naltrexone Hydrochloride ( Opioid receptors )	Opioid-Related Disorders More	Approved
Tropisetron Mesylate ( HTR3 )	Chemotherapy-induced nausea and vomiting More	Approved